The LATITUDE Patient Management System by Boston Scientific has FDA approval to be used in virtually all of the company's implantable defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds). This approval increases the number of patients eligible to receive the benefits of home monitoring by more than 150,000 in the U.S.
LATITUDE home monitoring is available to eligible patients with non-wireless devices, supporting nearly all models in the PRIZM and VITALITY families of ICDs and the RENEWAL family of CRT-Ds. To receive the benefits of remote monitoring, eligible patients can be enrolled in the LATITUDE system by their physician. Boston Scientific anticipates this technology will be available beginning next year.
Patients with nonwireless devices will now be able to benefit from the convenience of remote follow-ups and the knowledge that both their heart failure and device status can be monitored while they are at home. Regular monitoring of a patient's heart failure status allows for earlier notification of clinical events, giving physicians the opportunity to intervene faster and potentially prevent further complications.